Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 27, 2014
Pharmacy Choice - News - Pharmaceutical Development - August 27, 2014

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 134     Next >>     Go To Page:

8/27/14 - Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis In Patients With Relapsed And Advanced Refractory Multiple Myeloma
By a News Reporter-Staff News Editor at Biotech Week Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival. "While it is unfortunate that the FOCUS study did not meet its primary endpoint of overall survival, we believe the results fro
8/27/14 - FDA Approves Genentech's Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
By a News Reporter-Staff News Editor at Biotech Week Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration approved Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix. "With this appr
8/27/14 - Flex Pharma Announces Positive Results from Human Clinical Studies
By a News Reporter-Staff News Editor at Biotech Week Flex Pharma, Inc., a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, announced positive clinical results of its proprietary product for preventing muscle cramps. With these positive results in healthy volunteers, we plan to initiate effi
8/27/14 - Ignyta Announces Second Quarter 2014 Company Highlights and Financial Results
By a News Reporter-Staff News Editor at Biotech Week Ignyta, Inc., an oncology precision medicine biotechnology company, announced company highlights and financial results for the second quarter ended June 30, 2014. "Since the beginning of the second quarter, we have continued to make solid progress toward our goal of becoming a leading precisio
8/27/14 - Liquidia Technologies to Present New Data Supporting the Role of Particle Size and Shape in Vaccine Development
By a News Reporter-Staff News Editor at Vaccine Weekly Liquidia Technologies announced that it will present new data demonstrating the influence of tunable PRINT particle characteristics on the immune response as a component of vaccine development. Results from this preclinical study will be presented at the 9th Annual ImVacS, The Immunotherap
8/27/14 - Patent Application Titled "Compound for Inhibiting Glutathione S-Transferase Omega 1 Activity, Pharmaceutical Composition Containing Thereof, and...
Patent Application Titled "Compound for Inhibiting Glutathione S-Transferase Omega 1 Activity, Pharmaceutical Composition Containing Thereof, and Method for Synthesizing the Same" Published Online. By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent...
8/27/14 - Patent Issued for Arylamino N-Heteraryl Compounds as MEK Inhibitors
By a News Reporter-Staff News Editor at Biotech Week Merck Serono S.A. has been issued patent number 8802703, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventors are Goutopoulos, Andreas; Askew, Jr., Benny C.; Diep, Nhut Kiet; Karra, Srinivasa R.; Schwarz, Matthias; Yu, Henry. This patent
8/27/14 - Patent Issued for Modified Recombinant Human Endostatin and Uses
By a News Reporter-Staff News Editor at Journal of Engineering According to news reporting originating from Alexandria, Virginia, by VerticalNews journalists, a patent by the inventors Yao, Wenbing; Tian, Hong; Xu, Xiangyang; Li, Hairui; Dong, Yue; Gao, Xiangdong, filed on September 4, 2008, was published online on August 12, 2014. The assignee f
8/27/14 - Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine
By a News Reporter-Staff News Editor at Biotech Week Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086, the company's vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 thr
8/27/14 - Researchers Submit Patent Application, "Cell Therapy for the Treatment of Neurodegeneration", for Approval
By a News Reporter-Staff News Editor at Biotech Week From Washington, D.C., NewsRx journalists report that a patent application by the inventors Sasaki, Keishin; Chase, Thomas N.; Koga, Minako, filed on February 6, 2013, was made available online on August 14, 2014. The patent's assignee is Nc Medical Research Inc.. For example, Alzheimer's disea
8/27/14 - Researchers Submit Patent Application, "Topical Antiviral Formulations", for Approval
By a News Reporter-Staff News Editor at Biotech Week From Washington, D.C., NewsRx journalists report that a patent application by the inventors Brown, Darby C.; Brown, Kristen A., filed on December 2, 2013, was made available online on August 14, 2014. The patent's assignee is 3 B Pharmaceuticals, Inc.. News editors obtained the following quote
8/27/14 - Seattle Genetics Initiates Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma
By a News Reporter-Staff News Editor at Biotech Week Seattle Genetics, Inc. announced the initiation of a phase 1 clinical trial evaluating SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma. "CD70 is a very promising ADC antigen, which is highly expressed in both NHL and RCC, and has mini
8/27/14 - Tolero Pharmaceuticals and Eutropics Announce Data Demonstrating Clinical Utility of Praedicare Dx in Guiding New Drug Treatment of CLL Patients
By a News Reporter-Staff News Editor at Biotech Week Eutropics, Inc, and Tolero Pharmaceuticals, Inc, announced that clinical study results demonstrating a predictive biomarker for Chronic Lymphocytic Leukemia patient response to treatment with Toleros' experimental drug alvocidib were published in the medical journal Leukemia. The study, perform
8/25/14 - "Recombinant Butyrylcholinesterases and Truncates Thereof" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Bioterrorism Week A patent application by the inventors Yim, Kalvin; Danso, Steven; Hausknecht, Edward, filed on April 3, 2014, was made available online on August 14, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to PharmA
8/25/14 - AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results
By a News Reporter-Staff News Editor at Clinical Trials Week AcelRx Pharmaceuticals, Inc.,, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results for the three and six months ended June 30, 2014. Since the receipt of
8/25/14 - BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA
By a News Reporter-Staff News Editor at Clinical Trials Week BioDelivery Sciences International, Inc. announced that along with its commercial partner, Endo Pharmaceuticals, engaged in a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding BEMA Buprenorphine for the management of pain severe enough to req
8/25/14 - Clinical trial tests COXEN model to predict best treatment for bladder cancer
Now a clinical trial recently approved by the National Cancer Institute will open at the University of Colorado Cancer Center and nationally via the Southwest Oncology Group to test the COXEN model in bladder cancer- can it predict which cancers will and which cancers will not respond to two common chemotherapies? If we treat a bladder cancer with.
8/25/14 - Data on Clinical Trials and Studies Reported by Researchers at Royal Hallamshire Hospital (Constipation-predominant irritable bowel syndrome: A...
Data on Clinical Trials and Studies Reported by Researchers at Royal Hallamshire Hospital. By a News Reporter-Staff News Editor at Clinical Trials Week Research findings on Clinical Research are discussed in a new report. The news reporters obtained a quote from the research from Royal Hallamshire Hospital, "Conventional pharmacologic and...
8/25/14 - FDA Advisory Committee Recommends Approval of Tiotropium Respimat for the Maintenance Treatment of COPD
By a News Reporter-Staff News Editor at Clinical Trials Week Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee voted that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term,...
8/25/14 - FDA Approves BELSOMRA suvorexant for the Treatment of Insomnia
By a News Reporter-Staff News Editor at Clinical Trials Week Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has approved BELSOMRA for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA is a highly selective antagonist for orexin receptors.
8/25/14 - Findings from Massachusetts General Hospital Broaden Understanding of Clinical Trials and Studies (Extended treatment of Cushing's disease with...
By a News Reporter-Staff News Editor at Clinical Trials Week Current study results on Clinical Research have been published. According to news reporting originating from Boston, Massachusetts, by NewsRx correspondents, research stated, "In a previous 15- day, Phase II study of patients with de novo or persistent/recurrent Cushing's disease, treat
8/25/14 - Foundation Medicine Announces 2014 Second Quarter Results and Recent Highlights
By a News Reporter-Staff News Editor at Clinical Trials Week Foundation Medicine, Inc. reported financial and operating results for the quarter ended June 30, 2014. Total revenue of $14.5 million, 145% year-over-year growth. Foundation Medicine reported total revenue of $14.5 million in the second quarter of 2014, a 145% increase compared to $5.9
8/25/14 - Ignyta Appoints Adrian Senderowicz, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs
By a News Reporter-Staff News Editor at Clinical Trials Week Ignyta, Inc., an oncology precision medicine biotechnology company, announced that Adrian Senderowicz, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs. "Adrian's deep experience in clinical, research, development
8/25/14 - Infantile Spasm West Syndrome - Global Clinical Trials Review, H1, 2014
By a News Reporter-Staff News Editor at Clinical Trials Week Research and Markets has announced the addition of the "Infantile Spasm Global Clinical Trials Review, H1, 2014" report to their offering. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific a
8/25/14 - Kentucky professor develops new tool to prevent heroin deaths
By a News Reporter-Staff News Editor at Clinical Trials Week A new, lifesaving product aimed at reducing the death toll from heroin abuse- developed by a professor at the University of Kentucky College of Pharmacy- is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration. The product, a
Articles(s): 1 - 25 of 134     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415